Aarts, J.E.C.M. (2018). Samantha Adams Festschrift: coming of age – Samantha Adam’s career at Erasmus University Rotterdam. Applied Clinical Informatics (ACI), 9 (3), 493. doi: 10.1055/s-0038-1656523
Alemao, E., Al, M.J., Boonen, A.A., Stevenson, M.D., Verstappen, S., Michaud, K., Weinblatt, M.E. & Rutten – van Molken, M.P.M.H. (2018). Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. PLoS One (print), 13 (10). doi: 10.1371/journal.pone.0205013
Alemao, E., Johal, S., Al, M.J. & Rutten – van Molken, M.P.M.H. (2018). Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis. Value in Health, 21 (2), 193-202. doi: 10.1016/j.jval.2017.05.020
Ansaripour, A., Uyl – de Groot, C.A. & Redekop, W.K. (2018). Response to ‘Comment on ”Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy”‘. Pharmacoeconomics (Print), 36 (3), 381-382. doi: 10.1007/s40273-018-0620-y
Ansaripour, A., Zendehdel, K., Tadayon, N., Sadeghi, F., Uyl – de Groot, C.A. & Redekop, W.K. (2018). Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran. PLoS One (online), 13 (10). doi: 10.1371/journal.pone.0205079
Attema, A.E., Bleichrodt, H. & l’Haridon, O. (2018). Ambiguity preferences for health. Health Economics, 27 (11), 1699-1716. doi: 10.1002/hec.3795
Attema, A.E., Bleichrodt, H., l’Haridon, O., Peretti-Watel, P. & Seror, V. (2018). Discounting health and money: New evidence using a more robust method. Journal of Risk and Uncertainty, 56 (2), 117-140. doi: 10.1007/s11166-018-9279-1
Baal, P.H.M. van, Perry-Duxbury, M.S., Bakx, P.L.H., Versteegh, M.M., Doorslaer, E.K.A. van & Brouwer, W.B.F. (2018). A cost-effectiveness threshold based on the marginal returns of cardiovascular hospital spending. Health Economics, 28 (1), 87-100. doi: 10.1002/hec.3831
Becker, F., Anokye, N., Bekker – Grob, E.W. de, Higgins, A., Relton, C., Strong, M. & Fox-Rushby, J. (2018). Women’s preferences for alternative financial incentive schemes for breastfeeding: a discrete choice experiment. PLoS One (online), 13 (3):e0194231. doi: 10.1371/journal.pone.0194231
Bekker – Grob, E.W. de, Veldwijk, J., Jonker, M.F., Donkers, B., Huisman, J., Buis, S., Swait, J., Lancsar, E., Witteman, C., Bonsel, G.J. & Bindels, P.J.E. (2018). The impact of vaccination and patient characteristics on influenza vaccination uptake of elderly people: A discrete choice experiment. Vaccine, 36 (11), 1467-1476. doi: 10.1016/j.vaccine.2018.01.054
Blom, J.W., van den Hout, W., Elzen, W. den, Drewes, Y., Bleijenberg, N., Fabbricotti, I.N., Jansen, A., Kempen, G.I.J.M., Koopmans, R., Looman, W.M., Melis, R., Metzelthin, S.F., Moll van Charante, E., Muntinga, M., Numans, M.E., Ruikes, F., Spoorenberg, S., Stijnen, T., Suijker, J.J., De Wit, N.J., Wynia, K., Wind, A. & Gussekloo, J. (2018). Effectiveness and cost-effectiveness of proactive and multidisciplinary integrated care for older people with complex problems in general practice: an individual participant data meta-analysis. Age & Ageing, 47, 705-714. doi: 10.1093/ageing/afy091
Brouwer, W.B.F., Baal, P.H.M. van, Exel, N.J.A. van & Versteegh, M.M. (2018). When is it too expensive? Cost-effectiveness thresholds and health care decision-making. European Journal of Health Economics (HEPAC). doi: 10.1007/s10198-018-1000-4
Buyukkaramikli, N.C., Groot, S. de, Riemsma, R., Fayter, D., Armstrong, N., Portegijs, P., Duffy, S., Kleijnen, J. & Al, M.J. (2018). Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics (Print). doi: 10.1007/s40273-018-0708-4
Castagné, R., Garès, M., Karimi, M., Chadeau-Hyam, M., Vineis, P., Delpierre, C., Kelly-Irving, M., Mackenbach, J.P., Nusselder, W.J., Rubio Valverde, J.R., Vollenweider, P. & Zins, M. (2018). Allostatic load and subsequent all-cause mortality: which biological markers drive the relationship? Findings from a UK birth cohort. European Journal of Epidemiology, 33 (5), 441-458. doi: 10.1007/s10654-018-0364-1
Dickson, R., Boland, A., Duarte, R., Kotas, E., Woolacott, N., Hodgson, R., Riemsma, R., Grimm, S., Ramaekers, B., Joore, M., Buyukkaramikli, N.C., Kaltenthaler, E., Stevenson, M., Pandor, A., Edwards, S., Hoyle, M., Shepherd, J., Armoiry, X. & Brazzelli, M. (2018). EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties. Applied Health Economics and Health Policy, 16 (4), 429-432. doi: 10.1007/s40258-018-0393-7
Eeren, H. van, Goossens, L.M.A., Scholte, R., Busschbach, J.J. van & Rijken, R.E.A. van der (2018). Multisystemic Therapy and Functional Family Therapy Compared on their Effectiveness Using the Propensity Score Method. Journal of Abnormal Child Psychology, 46 (5), 1037-1050. doi: 10.1007/s10802-017-0392-4
Etnel, J.R.G., Grashuis, P., Huygens, S.A., Pekbay, B., Papageorgiou, G., Helbing, W.A., Roos-Hesselink, J.W., Bogers, A.J.J.C., Mokhles, M.M. & Takkenberg, J.J.M. (2018). The Ross Procedure: A Systematic Review, Meta-Analysis, and Microsimulation. Circulation-cardiovascular Quality And Outcomes, 11 (12):e004748. doi: 10.1161/circoutcomes.118.004748
Franken, M.G., Kanters, T.A., Coenen, J.L., De Jong, P., Koene, H.R., Lugtenburg, P.J., Jager, A. & Uyl-de Groot, C.A. de (2018). Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands. Anti-Cancer Drugs, 29 (8), 791-801. doi: 10.1097/CAD.0000000000000648
Franken, M.G., Leeneman, B., Jochems, A., Schouwenburg, M.G., Aarts, M., Akkooi, A.C.J., Berkmortel, F. van den, Eertwegh, A.J.M. Van den, Groot, J. de, Hoeven, J.J.M. van der, Hospers, G.A.P., Kapiteijn, E., Koornstra, R.H., Kruit, W.H.J., Louwman, M., Piersma, D., Rijn, R.S. van, Suijkerbuijk, K., Tije, A. ten, Vreugdenhil, G., Wouters, M.W.J.M., Zeijl, M., Haanen, J. & Uyl – de Groot, C.A. (2018). Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands. Anti-Cancer Drugs, 29 (6), 579-588. doi: 10.1097/CAD.0000000000000628
Franken, M.G., Corro Ramos, I., Los, J. & Al, M.J. (2018). The increasing importance of a continence nurse specialist to improve outcomes and save costs of urinary incontinence care: an analysis of future policy scenarios. BMC Family Practice, 19 (31). doi: 1186/s12875-018-0714-9
Uyl – de Groot, C.A., Rooijen, E.M. van, Punt, C.J.A. & Pescott, C.P. (2018). Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands. Health Economics Review, 8 (1), 13.
Uyl – de Groot, C.A. & Lowenberg, B. (2018). Reply to ‘Economic comments on proposal for a novel cancer drug pricing model’. Nature Reviews Clinical Oncology, 15 (9). doi: 10.1038/s41571-018-0084-1
Uyl – de Groot, C.A. & Lowenberg, B. (2018). Reply to ‘Response to proposal for a novel cancer drug pricing model’. Nature Reviews Clinical Oncology, 15 (8), 528-529. doi: 10.1038/s41571-018-0063-6
Uyl – de Groot, C.A. & Lowenberg, B. (2018). Sustainability and affordability of cancer drugs: a novel pricing model. Nature Reviews Clinical Oncology, 15 (7), 405-406. doi: 10.1038/s41571-018-0027-x
Groot, S. de, Enters-Weijnen, C.F., Geelhoed-Duijvestijn, P.H. & Kanters, T.A. (2018). A cost of illness study of hypoglycaemic events in insulin-treated diabetes in the Netherlands. BMJ Open, 8 (3). doi: 10.1136/bmjopen-2017-019864
Groot, S. de, Redekop, W.K., Versteegh, M.M., Sleijfer, S., Oosterwijk, E., Kiemeney, L.A.L.M. & Uyl-de Groot, C.A. de (2018). Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma. Quality of Life Research. doi: 10.1371/journal.pone.0177364
Grustam, A., Severens, J.L., De Massari, D., Buyukkaramikli, N.C., Koymans, R. & Vrijhoef, H.J.M. (2018). Cost-effectiveness analysis in telehealth: a comparison between home telemonitoring, nurse telephone support, and usual care in chronic heart failure management. Value in Health, 21 (7), 772-782.
Hermans, J., Reijman, M., Goossens, L.M.A., Verburg, H., Bierma-Zeinstra, S.M.A. & Koopmanschap, M.A. (2018). Cost-Utility Analysis of High Molecular Weight Hyaluronic Acid for Knee Osteoarthritis in Everyday Clinical Care in Patients at a Working Age: An Economic Evaluation of a Randomized Clinical Trial. Arthritis Care & Research, 70 (1), 89-97. doi: 10.1002/acr.23242
Hond, A.A.H. de, Bakx, P. & Versteegh, M.M. (2018). Can time heal all wounds? An empirical assessment of adaptation to functional limitations in an older population. Social Science & Medicine. doi: 10.1016/j.socscimed.2018.12.028
Hubens, K., Arons, A.M.M. & Krol, H.M. (2018). Measurement and evaluation of quality of life and well-being in individuals having or having had fertility problems: a systematic review. European Journal of Contraception and Reproductive Health Care. doi: 10.1080/13625187.2018.1539161
Huygens, S.A., Goossens, L.M.A., Erkelens, J.A. van, Takkenberg, J.J.M. & Rutten – van Molken, M.P.M.H. (2018). How much does a heart valve implantation cost and what are the health care costs afterwards? Open Heart, 5 (1):UNSP e000672. doi: 10.1136/openhrt-2017-000672
Huygens, S.A., Takkenberg, J.J.M. & Rutten – van Molken, M.P.M.H. (2018). Systematic review of model-based economic evaluations of heart valve implantations. The European Journal Of Health Economics, 19 (2), 241-255. doi: 10.1007/s10198-017-0880-z
Jochems, A., Leeneman, B., Franken, M.G., Schouwenburg, M.G., Aarts, M., Akkooi, A.C.J. van, Berkmortel, F. van den, Eertwegh, A.J.M. Van den, Groenewegen, G., Groot, J. de, Haanen, J., Hospers, G.A.P., Kapiteijn, E., Koornstra, R.H., Kruit, W.H.J., Louwman, M., Piersma, D., Rijn, R.S. van, Tije, A. ten, Vreugdenhil, G., Wouters, M.W.J.M., Uyl – de Groot, C.A. & Hoeven, J.J.M. van der (2018). Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands. Anti-Cancer Drugs, 29 (6), 572-578. doi: 10.1097/CAD.0000000000000629
Jonker, M.F., Donkers, B., Bekker – Grob, E.W. de & Stolk, E.A. (2018). Advocating a Paradigm Shift in Health-State Valuations: The Estimation of Time-Preference Corrected QALY Tariffs. Value in Health, 21 (8), 993-1001. doi: 10.1016/j.jval.2018.01.016
Jonker, M.F., Donkers, B., Bekker – Grob, E.W. de & Stolk, E.A. (2018). The Effect of Level Overlap and Color Coding on Attribute Non-attendance in Discrete Choice Experiments. Value in Health, 21 (7), 767-771. doi: 10.1016/j.jval.2017.10.002
Kanters, T.A., Thio, H.B. & Hakkaart – van Roijen, L. (2018). Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria. British Journal of Dermatology, 179 (3), 702-708. doi: 10.1111/bjd.16476
Kanters, T.A., Redekop, W.K. & Hakkaart – van Roijen, L. (2018). International differences in patient access to ultra-orphan drugs. Health Policy and Technology, 7, 57-64. doi: 10.1016/j.hlpt.2017.12.001
Knies, S., Severens, J.L. & Brouwer, W.B.F. (2018). Integrating clinical and economic evidence in clinical guidelines: More needed than ever! Journal of Evaluation in Clinical Practice. doi: 10.1111/jep.12936
Krugten, F.C.W. van, Goorden, M., Balkom, A.J.L.M. van, Spijker, J., Brouwer, W.B.F. & Hakkaart-van Roijen, L. (2018). Indicators to facilitate the early identification of patients with major depressive disorder in need of highly specialized care: A concept mapping study. Depression and Anxiety, 35 (4), 346-352. doi: 10.1002/da.22741
Leijten, F.R.M., Hoedemakers, M.J., struckmann, V., Kraus, M., Cheraghi-Sohi, S., Zemplényi, A., Ervik, R., Vallvég, C., Huiĉh, M., Czypionka, T., Boland, M. & Rutten – van Molken, M.P.M.H. (2018). Defining good health and care from the perspective of persons with multi-morbidity: Results from a qualitative study of focus groups in eight European countries. BMJ Open, 8. doi: 10.1136/bmjopen-2017-021072
Leijten, F.R.M., struckmann, V., van Ginneken, E., Czypionka, T., Kraus, M., Reiss, M., Tsiachristas, A., Boland, M., Bont, A.A. de, Bal, R.A. & Molken, M.P.M.H. van (2018). The SELFIE framework for integrated care for multi-morbidity: Development and description. Health Policy, 122, 12-22. doi: 10.1016/j.healthpol.2017.06.002
Lenk, E.J., Redekop, W.K., Luyendijk, M., Fitzpatrick, C., Niessen, L., Stolk, W.A., Tediosi, F., Rijnsburger, A.J., Bakker, R., Hontelez, J.A.C., Richardus, J.H., Jacobson, J., Rutte, E.A. Le, Vlas, S.J. de & Severens, J.L. (2018). Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease. PLoS Neglected Tropical Diseases (online), 12 (3):e0006250. doi: 10.1371/journal.pntd.0006250
Lim, S., Jonker, M.F., Oppe, M., Donkers, B. & Stolk, E.A. (2018). Severity-Stratified Discrete Choice Experiment Designs for Health State Evaluations. Pharmacoeconomics (Print), 36 (11), 1377-1389. doi: 10.1007/s40273-018-0694-6
Looman, W.M., Huijsman, R. & Fabbricotti, I.N. (2018). The (cost-)effectiveness of preventive, integrated care for community-dwelling frail older people: A systematic review. Health & Social Care in the Community, april, 1-30. doi: 10.1111/hsc.12571
Looman, W.M., Fabbricotti, I.N., Blom, J.W., Jansen, A., Lutomski, J., Metzelthin, S.F. & Huijsman, R. (2018). The frail older person does not exist: development of frailty profiles with latent class analysis. BMC Geriatrics, 18 (84), 1-11. doi: 10.1186/s12877-018-0776-5
Rutten – van Molken, M.P.M.H., Leijten, F.R.M., Hoedemakers, M.J., Tsiachristas, A., Verbeek, N.A., Karimi, M., Bal, R.A., de Bont, A., Islam, K., Askildsen, J.E., Czypionka, T., Kraus, M., Huic, M., Pitter, J.G., Vogt, V., Stokes, J. & Baltaxe, E. (2018). Strengthening the evidence-base of integrated care for people with multi-morbidity in Europe using Multi-Criteria Decision Analysis (MCDA). Bmc Health Services Research, 18 (1), 576.
Mulders-Manders, C.M., Kanters, T.A., Daele, P.L.A. van, Hoppenreijs, E., Legger, G.E., Laar, J.A.M. van, Simon, A. & Roijen, L. Hakkaart-van (2018). Decreased quality of life and societal impact of cryopyrin-associated periodic syndrome treated with canakinumab: a questionnaire based cohort study. Orphanet Journal of Rare Diseases, 13:59. doi: 10.1186/s13023-018-0799-1
Nestler-Parr, S., Korchagina, D., Toumi, M., Pashos, C.L., Blanchette, C., Molsen, E., Morel, T., Simoens, S., Kalo, Z., Gatermann, R. & Redekop, W.K. (2018). Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group. Value in Health, 21 (5), 493-500. doi: 10.1016/j.jval.2018.03.004
Noordman, B.J., Bekker – Grob, E.W. de, Coene, P., Harst, E., Lagarde, S.M., Shapiro, J., Wijnhoven, B.P.L. & Lanschot, J.J.B. van (2018). Patients’ preferences for treatment after neoadjuvant chemoradiotherapy for oesophageal cancer. British Journal of Surgery, 105 (12), 1630-1638. doi: 10.1002/bjs.10897
Ommen-Nijhof, A. van, Konings, I.R., Zeijl, C.J.J. van, Uyl – de Groot, C.A., Noort, V. van der, Jager, A. & Sonke, G. (2018). SONIA study steering committee. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial. Bmc Cancer, 18 (1), 1146-1153. doi: 10.1186/s12885-018-4978-1
Oosten, L.E.M., Chamuleau, M., Thielen, W.F., de Wreede, L.C., Siemes, C., Doorduijn, J.K., Smeekes, O.S., Kersten, M., Hardi, L., Baars, J.W., Demandt, A.M.P., Stevens, W., Nijland, G.W., Uyl-de Groot, C.A. de, Kluin, P.M., de Jong, D. & Veelken, H. (2018). Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens. Annals of Hematology, 97 (2), 255-266. doi: 10.1007/s00277-017-3167-7
Patty, N.J.S., Koopmanschap, M.A. & Holtzer-Goor, K.M. (2018). A cost-effectiveness study of ICT training among the visually impaired in the Netherlands. BMC OPHTHALMOLOGY, 18 (98). doi: 10.1186/s12886-018-0761-y
Peultier, A.M.M., Redekop, W.K., Coche, E. & Severens, J.L. (2018). What are the images used to diagnose and assess suspected strokes?: A systematic literature review of care in four European countries. Expert review of pharmacoeconomics & outcomes research, Volume 18 (2). doi: 10.1080/14737167.2018.1429270
Postma, J.P., Dongen – Leunis, A. van, Hakkaart – van Roijen, L. & Bal, R.A. (2018). Eindrapportage experiment Topzorg. (Extern rapport). Rotterdam: Erasmus School of Health Policy and Management
Redekop, W.K. (2018). Fake news, big data, and the opportunities and threats of targeted actions. Health Policy and Technology, 7 (2), 113-114. doi: 10.1016/j.hlpt.2018.05.001
Redekop, W.K., Bakker, L.J. & Aarts, J.E.C.M. (2018). Healthcare problems cannot be solved using health technologies alone: The example of precision medicine. Health Policy and Technology, 7 (1), 3-4. doi: 10.1016/j.hlpt.2018.01.006
Ruggeri, K., Stuhlreyer, J.P., Immonen, J., Mareva, S., Paul, A.F., Robbiani, A., Thielen, W.F., Gelashvili, A., Cavassini, F. & Naru, F. (2018). Policy evaluation. In K. Ruggeri (Ed.), Behavioral Insight for Public Policy: Concepts and Cases (pp. 3). New York: Routledge
Schouwenburg, M.G., Jochems, A., Leeneman, B., Franken, M.G., Eertwegh, A.J.M. Van den, Haanen, J., Zeijl, M.C.T. van, Aarts, M., Akkooi, A.C.J., Berkmortel, F. van den, Blokx, W.A.M., Groot, J. de, Hospers, G.A.P., Kapiteijn, E., Koornstra, R.H., Kruit, W.H., Louwman, M., Piersma, D., Rijn, R.S. van, Suijkerbuijk, K., Tije, A. ten, Vreugdenhil, G., Wouters, M. & Hoeven, J.J.M. van der (2018). Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes. Melanoma Research, 28 (4), 326-332. doi: 10.1097/cmr.0000000000000453
Sinnaeve, P., Bosch, L.M.C., Hakkaart – van Roijen, L. & Vansteelandt, S. (2018). Effectiveness of step-down versus outpatient dialectical behaviour therapy for patients with severe levels of borderline personality disorder: a pragmatic randomized controlled trial. BioMed Central, 2018 (5:12), 1-10. doi: 10.1186/s40479-018-0089-5
Stiphout, F. van, Rijkom, J. Zwart-van, Versmissen, J., Koffijberg, H., Aarts, J.E.C.M., Sijs, I.H. van der, Gelder, T. van, Man, R.A. de, Roes, C.B., Egberts, T. & Braak, E. ter (2018). Effects of training physicians in electronic prescribing in the outpatient setting on clinical, learning and behavioural outcomes: a cluster randomized trial. British Journal of Clinical Pharmacology, 84 (6), 1187-1197. doi: 10.1111/bcp.13540
Stokes, J., struckmann, V., Kristensen, S., Fuchs, S., van Ginneken, E., Tsiachristas, A., Rutten – van Molken, M.P.M.H. & Sutton, M. (2018). Towards incentivising integration: A typology of payments for
integrated care. Health Policy. doi: 10.1016/j.healthpol.2018.07.003
Thielen, W.F., Büyükkaramikli, N.C., Riemsma, R., Fayter, D., Armstrong, N., Wei, C., Huertas Carrera, V., Misso, K., Worthy, G., Kleijnen, J. & Corro Ramos, I. (2018). Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma. Pharmacoeconomics (Print). doi: 10.1007/s40273-018-0740-4
Thielen, W.F., Blommestein, H.M., Oosten, L.E.M., Calkoen, F.G., Lankester, A.C., Zwaginga, J., Le Blanc, K., Redondo, A., Sánchez‐Guijo, F., Algeri, M., Locatelli, F., Fibbe, W.E. & Uyl – de Groot, C.A. (2018). Second‐line treatment for acute graft‐versus‐host disease with mesenchymal stromal cells: A decision model. European Journal of Haematology, 101 (5), 676-683. doi: 10.1111/ejh.13158
Vaidya, A., Kleinegris, M., Severens, J.L., Ramaekers, B.L., Cate-Hoek, A.J. ten, Cate, H. ten & Joore, M.A. (2018). Comparison of EQ-5D and SF-36 in untreated patients with symptoms of intermittent claudication. Journal of comparative effectiveness research, 7 (6), 535-548. doi: 10.2217/cer-2017-0029
Van de Ree, C.L.P., Ploegsma, K., Kanters, T.A., Roukema, J.A. & De Jongh, M.A.C. (2018). Care-related Quality of Life of informal caregivers of the elderly after a hip fracture. Journal of Patient-Reported Outcomes, 2:23. doi: 10.1186/s41687-018-0048-3
Verelst, S.G.R., Blommestein, H.M., Groot, S. de, Gonzalez-McQuire, S., DeCosta, L., de Raad, J.B., Uyl-de Groot, C.A. de & Sonneveld, P. (2018). Long-term Outcomes in Patients With Multiple Myeloma: A Retrospective Analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS). HemaSphere, 2 (4). doi: 10.1097/HS9.0000000000000045
Vestjens, L., Cramm, J.M., Birnie, E. & Nieboer, A.P. (2018). Evaluating an integrated primary care approach to improve well-being among frail community-living older people: A theory-guided study protocol. BMC Geriatrics. doi: 10.1186/s12877-018-0832-1
Westgeest, H.M., Uyl-de Groot, C.A. de, Moorselaar, R.J.A. van, Wit, R. de, Bergh, A.C.M. van den, Coenen, J.L.L.M., Beerlage, H.P., Hendriks, M.P., Bos, M., Berg, P. van den, Wouw, A. van de, Spermon, T., Boerma, M.O., Geenen, M.M., Tick, L.W., Polee, M.B., Bloemendal, H., Cordia, I., Peters, F.P.J., Vos, A.I. de, van den Bosch, J. van den, Eertwegh, A.J.M. Van den & Gerritsen, W. (2018). Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry. European Urology, 4 (5), 694-701. doi: 10.1016/j.euf.2016.09.008
Struckmann, V., Leijten, F.R.M., van Ginneken, E., Kraus, M., Reiss, M., Spranger, O., Boland, M., Czypionka, T., Busse, R. & Rutten – van Molken, M.P.M.H. (2018). Relevant models and elements of integrated care for multi-morbidity: Results of a scoping review. Health Policy, 122 (1), 23-35. doi: 10.1016/j.healthpol.2017.08.008